Floatz logo

Zanzalintinib

Extra-Pancreatic Neuroendocrine Tumor (epNET)

ExelixisSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

61 Active assets in the Extra-Pancreatic Neuroendocrine Tumor (epNET) cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

Zanzalintinib is also rated in:

pancreatic neuroendocrine tumorDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →